{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T02:38:15Z","timestamp":1777257495333,"version":"3.51.4"},"reference-count":86,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>The US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for SARS-CoV-2 assays encompassed both in vitro diagnostic and laboratory-developed tests. Related testing data and documents from EUAs were published on the FDA website as PDF files, constituting a rich data resource.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To highlight the value of structured descriptive and validation data and provide recommendations on improving the quality, accessibility, and shareability of the FDA\u2019s digital resources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>SARS-CoV-2 diagnostics EUAs and related files were acquired from the FDA, and data were extracted through an iterative manual or automated process with quality assurance in accordance with a set of data entry definitions to generate a data product (ie, data analysis and presentation of data into tables, graphs, and reports, optionally including different data sets) that could be disseminated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Four challenges limited the usability of FDA EUA data, including (1) distinguishing EUA tests owing to similar names or inconsistent naming conventions; (2) document location and tracking owing to inconsistent EUA document identifiers, resource locators, and versioning; (3) data location and retrieval owing to heterogeneous structure and data formatting within EUA documentation; and (4) maintenance of existing data owing to lack of clear and traceable communication around EUA amendments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Converging efforts from disparate groups to extract and synthesize FDA test data reveal an unaddressed need for better organization and communication. Existing FDA data reporting systems must be improved and adapted for the demands of the connected data science era.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2025-0144-oa","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:14:23Z","timestamp":1768990463000},"page":"381-390","source":"Crossref","is-referenced-by-count":0,"title":["Challenges in Structuring SARS-CoV-2 Emergency Use Authorization Diagnostics Data: Leveraging Findable, Accessible, Interoperable, and Reusable Principles for the Next Era of Diagnostic Data Transparency"],"prefix":"10.5858","volume":"150","author":[{"given":"Alexander J.","family":"Phillips","sequence":"first","affiliation":[{"name":"From the Center of Complex Interventions, Cambridge, Massachusetts (Phillips, Dinakar, Bates Weinstock)"},{"name":"Effect Engineering Limited, London, United Kingdom (Phillips)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron L.","family":"Glieberman","sequence":"additional","affiliation":[{"name":"AdVeritasDx, Webster, Texas (Glieberman, Morrison, Reed, Baron, Borchers, Okda, Stone, Ishack, Rajesh, Creager)"},{"name":"MelliCell, Inc, Newton, Massachusetts (Glieberman)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Gallegos","sequence":"additional","affiliation":[{"name":"Association of Public Health Laboratories, Bethesda, Maryland (Gallegos, Merrick)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Morrison","sequence":"additional","affiliation":[{"name":"AdVeritasDx, Webster, Texas (Glieberman, Morrison, Reed, Baron, Borchers, Okda, Stone, Ishack, Rajesh, Creager)"},{"name":"Aspirant Strategy LLC, Webster, Texas (Morrison)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Reed","sequence":"additional","affiliation":[{"name":"AdVeritasDx, Webster, Texas (Glieberman, Morrison, Reed, Baron, Borchers, Okda, Stone, Ishack, Rajesh, Creager)"},{"name":"NaviDx Consulting, LLC, Mount Prospect, Illinois (Reed, Creager)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique T.","family":"Baron","sequence":"additional","affiliation":[{"name":"AdVeritasDx, Webster, Texas (Glieberman, Morrison, Reed, Baron, Borchers, Okda, Stone, Ishack, Rajesh, Creager)"},{"name":"BPS Bioscience, San Diego, California (Baron)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Dinakar","sequence":"additional","affiliation":[{"name":"From the Center of Complex Interventions, Cambridge, Massachusetts (Phillips, Dinakar, Bates Weinstock)"},{"name":"the Department of Medicine, Icahn School of Medicine, Mount Sinai Hospital, Boston, Massachusetts (Dinakar)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Borchers","sequence":"additional","affiliation":[{"name":"AdVeritasDx, Webster, Texas (Glieberman, Morrison, Reed, Baron, Borchers, Okda, Stone, Ishack, Rajesh, Creager)"},{"name":"the Department of Immunology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota (Borchers)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faten A.","family":"Okda","sequence":"additional","affiliation":[{"name":"AdVeritasDx, Webster, Texas (Glieberman, Morrison, Reed, Baron, Borchers, Okda, Stone, Ishack, Rajesh, Creager)"},{"name":"the Department of Host-Microbe Interactions, St. Jude Children\u2019s Research Hospital, Memphis, Tennessee (Okda)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Webb","family":"Stone","sequence":"additional","affiliation":[{"name":"AdVeritasDx, Webster, Texas (Glieberman, Morrison, Reed, Baron, Borchers, Okda, Stone, Ishack, Rajesh, Creager)"},{"name":"UrbanPonics, Newton, Pennsylvania (Stone)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujeewa Sampath","family":"Lellupitiyage Don","sequence":"additional","affiliation":[{"name":"the Department of Chemistry, University of Massachusetts Amherst, Amherst (Lellupitiyage Don)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie N.","family":"Ishack","sequence":"additional","affiliation":[{"name":"AdVeritasDx, Webster, Texas (Glieberman, Morrison, Reed, Baron, Borchers, Okda, Stone, Ishack, Rajesh, Creager)"},{"name":"the Department of Biomedical Engineering, New York University, New York City (Ishack)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer V.","family":"Rajesh","sequence":"additional","affiliation":[{"name":"AdVeritasDx, Webster, Texas (Glieberman, Morrison, Reed, Baron, Borchers, Okda, Stone, Ishack, Rajesh, Creager)"},{"name":"School of Medicine, UT Southwestern Medical Center, Dallas, Texas (Rajesh)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard S.","family":"Creager","sequence":"additional","affiliation":[{"name":"AdVeritasDx, Webster, Texas (Glieberman, Morrison, Reed, Baron, Borchers, Okda, Stone, Ishack, Rajesh, Creager)"},{"name":"NaviDx Consulting, LLC, Mount Prospect, Illinois (Reed, Creager)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha Bates","family":"Weinstock","sequence":"additional","affiliation":[{"name":"From the Center of Complex Interventions, Cambridge, Massachusetts (Phillips, Dinakar, Bates Weinstock)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung S.","family":"Luu","sequence":"additional","affiliation":[{"name":"Department of Pathology, UT Southwestern Medical Center, Dallas, Texas (Luu)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asiyah Yu","family":"Lin","sequence":"additional","affiliation":[{"name":"National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland (Lin)"},{"name":"Axle Informatics, LLC, North Bethesda, Maryland (Lin)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riki","family":"Merrick","sequence":"additional","affiliation":[{"name":"Association of Public Health Laboratories, Bethesda, Maryland (Gallegos, Merrick)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","reference":[{"key":"i1543-2165-150-5-381-b01","series-title":"J Mol Diagn","first-page":"1207","article-title":"Temporary Regulatory Deviations and the Coronavirus Disease 2019 (COVID-19) PCR Labeling Update Study indicate what laboratory-developed test regulation by the US Food and Drug Administration (FDA) could look like","volume":"23","author":"Marble","year":"2021","unstructured":"Marble HD,\nBard AZ,\nMizrachi MM,\nLennerz JK. Temporary Regulatory Deviations and the Coronavirus Disease 2019 (COVID-19) PCR Labeling Update Study indicate what laboratory-developed test regulation by the US Food and Drug Administration (FDA) could look like. J Mol Diagn. 2021;23:1207\u20131217. doi:10.1016\/j.jmoldx.2021.07.011"},{"key":"i1543-2165-150-5-381-b02","series-title":"J Mass Spectrom Adv Clin Lab","first-page":"1","article-title":"The VALIDity of laboratory developed tests: leave it to the experts","volume":"27","author":"Marzinke","year":"2022","unstructured":"Marzinke MA,\nClarke W,\nDietzen DJ,\nHoofnagle AN,\nMcMillin GA,\nWillrich MAV. The VALIDity of laboratory developed tests: leave it to the experts? J Mass Spectrom Adv Clin Lab. 2022;27:1\u20136. doi:10.1016\/j.jmsacl.2022.12.002"},{"key":"i1543-2165-150-5-381-b03","author":"Association of Public Health Laboratories. Association of Public Health Laboratories website","unstructured":"Association of Public Health Laboratories. Association of Public Health Laboratories website. https:\/\/www.aphl.org\/Pages\/default.aspx. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b04","article-title":"Helping communities translate science into action. Center of Complex Interventions website","author":"CCI","unstructured":"CCI. Helping communities translate science into action. Center of Complex Interventions website. https:\/\/centerofci.org\/. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b05","article-title":"AdVeritasDx website","author":"AdVeritasDx","unstructured":"AdVeritasDx. AdVeritasDx website. https:\/\/www.facebook.com\/AdVeritasDx\/. Accessed August 10, 2025."},{"issue":"1","key":"i1543-2165-150-5-381-b06","series-title":"Sci Data","first-page":"6","article-title":"The FAIR Guiding Principles for scientific data management and stewardship [erratum in","volume":"6","author":"Wilkinson","year":"2019","unstructured":"Wilkinson MD,\nDumontier M,\nAalbersberg IJ, et al. The FAIR Guiding Principles for scientific data management and stewardship [erratum in Sci Data. 2019;6(1):6. doi:10.1038\/s41597-019-0009-6]. Sci Data. 2016;3:160018. doi:10.1038\/sdata.2016.18"},{"key":"i1543-2165-150-5-381-b07","series-title":"J Am Med Inform Assoc","first-page":"211","article-title":"Structured product labeling improves detection of drug-intolerance issues","volume":"16","author":"Schadow","year":"2009","unstructured":"Schadow G. Structured product labeling improves detection of drug-intolerance issues. J Am Med Inform Assoc. 2009;16:211\u2013219. doi:10.1197\/jamia.M2933"},{"key":"i1543-2165-150-5-381-b08","article-title":"US Food and Drug Administration website","author":"FDA Broad Agency Announcement Day","year":"2022","unstructured":"FDA Broad Agency Announcement Day 2022. US Food and Drug Administration website. December 6, 2022. https:\/\/www.fda.gov\/science-research\/fda-broad-agency-announcement-day-2022-12062022. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b09","article-title":"Diagnostic (LIVD) test code mapping for SARS-CoV-2 tests. Centers for Disease Control and Prevention website","author":"LOINC In Vitro","unstructured":"LOINC In Vitro Diagnostic (LIVD) test code mapping for SARS-CoV-2 tests. Centers for Disease Control and Prevention website. https:\/\/www.cdc.gov\/csels\/dls\/livd-codes.html. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b10","series-title":"Semantic Interoperability for In Vitro Diagnostic Systems","author":"CLSI","year":"2023","unstructured":"CLSI. Semantic Interoperability for In Vitro Diagnostic Systems. 1st ed. CLSI Report AUTO17. Clinical and Laboratory Standards Institute; 2023."},{"key":"i1543-2165-150-5-381-b11","article-title":"Exploring the complexity of COVID-19 diagnostic tests. Center of Complex Interventions website","author":"Wattenberger","unstructured":"Wattenberger A,\nDinakar K,\nSousa J, et al. Exploring the complexity of COVID-19 diagnostic tests. Center of Complex Interventions website. https:\/\/interventions.centerofci.org\/pub\/exploring-covid-test-complexity\/release\/1. Accessed August 10, 2025."},{"key":"i1543-2165-150-5-381-b12","article-title":"COVID-19 RNA testing technology assessment. Center of Complex Interventions website","author":"Farzadfard","unstructured":"Farzadfard F,\nKang L,\nBates S, et al. COVID-19 RNA testing technology assessment. Center of Complex Interventions website. https:\/\/interventions.centerofci.org\/pub\/covid-testing-assessment\/release\/14. Accessed August 10, 2025."},{"key":"i1543-2165-150-5-381-b13","article-title":"Insights from structured SARS-2 diagnostics data. Center of Complex Interventions website","author":"Phillips","unstructured":"Phillips AJ. Insights from structured SARS-2 diagnostics data. Center of Complex Interventions website. https:\/\/interventions.centerofci.org\/pub\/structured-sars-2-diagnostic-data\/release\/1. Accessed August 10, 2025."},{"key":"i1543-2165-150-5-381-b14","article-title":"In vitro diagnostics EUAs\u2014molecular diagnostic tests for SARS-CoV-2","year":"2021","unstructured":"In vitro diagnostics EUAs\u2014molecular diagnostic tests for SARS-CoV-2. US Food and Drug Administration website. 2021. https:\/\/www.fda.gov\/medical-devices\/covid-19-emergency-use-authorizations-medical-devices\/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b15","article-title":"In vitro diagnostics EUAs\u2014antigen diagnostic tests for SARS-CoV-2","year":"2021","unstructured":"In vitro diagnostics EUAs\u2014antigen diagnostic tests for SARS-CoV-2. US Food and Drug Administration website. 2021. https:\/\/www.fda.gov\/medical-devices\/covid-19-emergency-use-authorizations-medical-devices\/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b16","article-title":"In vitro diagnostics Emergency Use Authorizations (EUAs)\u2014serology and other adaptive immune response tests for SARS-CoV-2. 2022. US Food and Drug Administration website","unstructured":"In vitro diagnostics Emergency Use Authorizations (EUAs)\u2014serology and other adaptive immune response tests for SARS-CoV-2. 2022. US Food and Drug Administration website. https:\/\/www.fda.gov\/medical-devices\/covid-19-emergency-use-authorizations-medical-devices\/in-vitro-diagnostics-emergency-use-authorizations-euas-serology-and-other-adaptive-immune-response. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b17","article-title":"Structured SARS-2 diagnostic data. Center of Complex Interventions Archive","author":"Phillips","unstructured":"Phillips AJ,\nBaron V. Structured SARS-2 diagnostic data. Center of Complex Interventions Archive. https:\/\/github.com\/centerofci-archive\/SARS-CoV-2-testing-kit-validation-data\/. Accessed November 26, 2023."},{"key":"i1543-2165-150-5-381-b18","article-title":"Files annotation server","author":"Phillips","unstructured":"Phillips AJ. Files annotation server. Center of Complex Interventions Archive. https:\/\/github.com\/AJamesPhillips\/anot8. Accessed November 26, 2023."},{"key":"i1543-2165-150-5-381-b19","article-title":"Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay","year":"2020","unstructured":"Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay. Wayback Machine website. June 13, 2020. https:\/\/web.archive.org\/web\/20200613101217\/https:\/\/www.fda.gov\/media\/137776\/download. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b20","article-title":"Infinity BiologiX TaqPath SARS-CoV-2","year":"2023","unstructured":"Infinity BiologiX TaqPath SARS-CoV-2. Wayback Machine website. May 11, 2023. https:\/\/web.archive.org\/web\/20230511163511\/https:\/\/www.fda.gov\/media\/137776\/download. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b21","article-title":"Emergency Use Authorization","year":"2021","unstructured":"Emergency Use Authorization. Wayback Machine website. February 28, 2021. https:\/\/web.archive.org\/web\/20210228023054\/https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b22","article-title":"In vitro diagnostics EUAs\u2014molecular diagnostic tests for SARS-CoV-2","year":"2021","unstructured":"In vitro diagnostics EUAs\u2014molecular diagnostic tests for SARS-CoV-2. Wayback Machine website. March 26, 2021. https:\/\/web.archive.org\/web\/20210326223647\/https:\/\/www.fda.gov\/medical-devices\/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b23","article-title":"Abbott RealTime SARS-CoV-2 assay, letter granting EUA amendment(s)","year":"2020","unstructured":"Abbott RealTime SARS-CoV-2 assay, letter granting EUA amendment(s). US Food and Drug Administration website. July 30, 2020. https:\/\/www.fda.gov\/media\/140667\/download?attachment. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b24","article-title":"Abbott RealTime SARS-CoV-2","year":"2020","unstructured":"Abbott RealTime SARS-CoV-2. Wayback Machine website. July 28, 2020. https:\/\/web.archive.org\/web\/20200728165808\/https:\/\/www.fda.gov\/media\/136258\/download. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b25","article-title":"Abbott RealTime SARS-CoV-2","year":"2020","unstructured":"Abbott RealTime SARS-CoV-2. Wayback Machine website. September 5, 2020. https:\/\/web.archive.org\/web\/20200905002031\/https:\/\/www.fda.gov\/media\/136258\/download. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b26","article-title":"Abbott RealTime SARS-CoV-2","year":"2020","unstructured":"Abbott RealTime SARS-CoV-2. Wayback Machine website. September 16, 2020. https:\/\/web.archive.org\/web\/20200916202527\/https:\/\/www.fda.gov\/media\/136258\/download. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b27","series-title":"J Clin Virol","first-page":"105611","article-title":"FDA trial regulation of laboratory developed tests (LDTs): an academic medical center\u2019s experience with Mpox in-house testing","volume":"169","author":"Caldera","year":"2023","unstructured":"Caldera JR,\nGray HK,\nGarner OB,\nYang S. FDA trial regulation of laboratory developed tests (LDTs): an academic medical center\u2019s experience with Mpox in-house testing. J Clin Virol. 2023;169:105611. doi:10.1016\/j.jcv.2023.105611"},{"key":"i1543-2165-150-5-381-b28","article-title":"In Vitro Diagnostic Products for Human Use. 21 CFR Part 809","unstructured":"In Vitro Diagnostic Products for Human Use. 21 CFR Part 809. Electronic Code of Federal Regulations (eCFR). https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-H\/part-809. Accessed January 1, 2025."},{"key":"i1543-2165-150-5-381-b29","series-title":"Am J Clin Pathol","first-page":"730","article-title":"Laboratory-developed tests and in vitro diagnostics: a regulatory overview for anatomic pathology","volume":"163","author":"Genzen","year":"2025","unstructured":"Genzen JR,\nMiller LJ,\nRets AV,\nAffolter KE. Laboratory-developed tests and in vitro diagnostics: a regulatory overview for anatomic pathology. Am J Clin Pathol. 2025;163:730\u2013743."},{"key":"i1543-2165-150-5-381-b30","article-title":"American Clinical Laboratory Association, et al v US Food and Drug Administration, et al (Case No. 4:24-CV-479-SDJ) and Association for Molecular Pathology, et al v US Food and Drug Administration, et al","unstructured":"American Clinical Laboratory Association, et al v US Food and Drug Administration, et al (Case No. 4:24-CV-479-SDJ) and Association for Molecular Pathology, et al v US Food and Drug Administration, et al (Case No. 4:24-CV-824-SDJ) LDT Final Judgment. Association of Molecular Pathology website. https:\/\/www.amp.org\/AMP\/assets\/File\/advocacy\/FDAFinalRule\/LDTFINALJUDGMENT033125.pdf?pass=18. Accessed August 10, 2025."},{"key":"i1543-2165-150-5-381-b31","article-title":"RFC 9110: HTTP semantics. Internet Engineering Task Force website","author":"Fielding","year":"2022","unstructured":"Fielding RT,\nNottingham M,\nReschke J. RFC 9110: HTTP semantics. Internet Engineering Task Force website. 2022. https:\/\/datatracker.ietf.org\/doc\/html\/rfc9110#section-8.8.1. Accessed March 14, 2025."},{"issue":"649","key":"i1543-2165-150-5-381-b32","series-title":"Sci Signal","first-page":"eabe4242","article-title":"COVID-19: all the wrong moves in all the wrong places","volume":"13","author":"Barrett","year":"2020","unstructured":"Barrett CD,\nYaffe MB. COVID-19: all the wrong moves in all the wrong places. Sci Signal. 2020;13(649):eabe4242. doi:10.1126\/scisignal.abe4242"},{"key":"i1543-2165-150-5-381-b33","article-title":"Coronavirus (COVID-19) update: FDA expedites review of diagnostic tests to combat COVID-19. US Food and Drug Administration website","author":"Hahn","year":"2020","unstructured":"Hahn SM. Coronavirus (COVID-19) update: FDA expedites review of diagnostic tests to combat COVID-19. US Food and Drug Administration website. March 30, 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-expedites-review-diagnostic-tests-combat-covid-19. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b34","article-title":"COVID-19 test directory\u2014FIND","author":"FINDDx","unstructured":"FINDDx. COVID-19 test directory\u2014FIND. https:\/\/www.finddx.org\/tools-and-resources\/dxconnect\/test-directories\/covid-19-test-directory\/. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b35","article-title":"Testing Commons. College of Health Solutions website","author":"Aspinall","unstructured":"Aspinall MG,\nWade NL. Testing Commons. College of Health Solutions website. https:\/\/chs.asu.edu\/diagnostics-commons\/testing-commons. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b36","article-title":"COVID-19 Diagnostics Dashboard","unstructured":"COVID-19 Diagnostics Dashboard. PATH website. https:\/\/www.path.org\/programs\/diagnostics\/covid-dashboard-covid-19-diagnostics-dashboard\/. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b37","article-title":"COVID-19 In Vitro Diagnostic Devices and Test Methods Database","year":"2023","unstructured":"COVID-19 In Vitro Diagnostic Devices and Test Methods Database. Joint Research Center website. 2023. https:\/\/covid-19-diagnostics.jrc.ec.europa.eu\/devices. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b38","series-title":"Nat Biotechnol","first-page":"1021","article-title":"The COVID-19 XPRIZE and the need for scalable, fast, and widespread testing","volume":"38","author":"MacKay","year":"2020","unstructured":"MacKay MJ,\nHooker AC,\nAfshinnekoo E, et al. The COVID-19 XPRIZE and the need for scalable, fast, and widespread testing. Nat Biotechnol. 2020;38:1021\u20131024. doi:10.1038\/s41587-020-0655-4"},{"issue":"2","key":"i1543-2165-150-5-381-b39","series-title":"JAMIA Open","first-page":"ooae032","article-title":"Analysis of laboratory data transmission between two healthcare institutions using a widely used point-to-point health information exchange platform: a case report","volume":"7","author":"Luu","year":"2024","unstructured":"Luu HS,\nCampbell WS,\nCholan RA, et al. Analysis of laboratory data transmission between two healthcare institutions using a widely used point-to-point health information exchange platform: a case report. JAMIA Open. 2024;7(2):ooae032. doi:10.1093\/jamiaopen\/ooae032"},{"issue":"1","key":"i1543-2165-150-5-381-b40","series-title":"Ann Lab Med","first-page":"12","article-title":"Laboratory data as a potential source of bias in healthcare artificial intelligence and machine learning models","volume":"45","author":"Luu","year":"2025","unstructured":"Luu HS. Laboratory data as a potential source of bias in healthcare artificial intelligence and machine learning models. Ann Lab Med. 2025;45(1):12\u201321. doi:10.3343\/alm.2024.0323"},{"issue":"8","key":"i1543-2165-150-5-381-b41","series-title":"J Am Med Inform Assoc","first-page":"1372","article-title":"Encoding laboratory testing data: case studies of the national implementation of HHS requirements and related standards in five laboratories","volume":"29","author":"Cholan","year":"2022","unstructured":"Cholan RA,\nPappas G,\nRehwoldt G, et al. Encoding laboratory testing data: case studies of the national implementation of HHS requirements and related standards in five laboratories. J Am Med Inform Assoc. 2022;29(8):1372\u20131380. doi:10.1093\/jamia\/ocac072"},{"issue":"1","key":"i1543-2165-150-5-381-b42","series-title":"Sci Data","first-page":"144","article-title":"The TRUST Principles for digital repositories","volume":"7","author":"Lin","year":"2020","unstructured":"Lin D,\nCrabtree J,\nDillo I, et al. The TRUST Principles for digital repositories. Sci Data. 2020;7(1):144. doi:10.1038\/s41597-020-0486-7"},{"key":"i1543-2165-150-5-381-b43","series-title":"Desirable Characteristics of Data Repositories for Federally Funded Research","author":"The National Science and Technology Council","year":"2022","unstructured":"The National Science and Technology Council. Desirable Characteristics of Data Repositories for Federally Funded Research. NSTC; 2022. doi:10.5479\/10088\/113528"},{"key":"i1543-2165-150-5-381-b01","series-title":"J Mol Diagn","first-page":"1207","article-title":"Temporary Regulatory Deviations and the Coronavirus Disease 2019 (COVID-19) PCR Labeling Update Study indicate what laboratory-developed test regulation by the US Food and Drug Administration (FDA) could look like","volume":"23","author":"Marble","year":"2021","unstructured":"Marble HD,\nBard AZ,\nMizrachi MM,\nLennerz JK. Temporary Regulatory Deviations and the Coronavirus Disease 2019 (COVID-19) PCR Labeling Update Study indicate what laboratory-developed test regulation by the US Food and Drug Administration (FDA) could look like. J Mol Diagn. 2021;23:1207\u20131217. doi:10.1016\/j.jmoldx.2021.07.011"},{"key":"i1543-2165-150-5-381-b02","series-title":"J Mass Spectrom Adv Clin Lab","first-page":"1","article-title":"The VALIDity of laboratory developed tests: leave it to the experts","volume":"27","author":"Marzinke","year":"2022","unstructured":"Marzinke MA,\nClarke W,\nDietzen DJ,\nHoofnagle AN,\nMcMillin GA,\nWillrich MAV. The VALIDity of laboratory developed tests: leave it to the experts? J Mass Spectrom Adv Clin Lab. 2022;27:1\u20136. doi:10.1016\/j.jmsacl.2022.12.002"},{"key":"i1543-2165-150-5-381-b03","author":"Association of Public Health Laboratories. Association of Public Health Laboratories website","unstructured":"Association of Public Health Laboratories. Association of Public Health Laboratories website. https:\/\/www.aphl.org\/Pages\/default.aspx. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b04","article-title":"Helping communities translate science into action. Center of Complex Interventions website","author":"CCI","unstructured":"CCI. Helping communities translate science into action. Center of Complex Interventions website. https:\/\/centerofci.org\/. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b05","article-title":"AdVeritasDx website","author":"AdVeritasDx","unstructured":"AdVeritasDx. AdVeritasDx website. https:\/\/www.facebook.com\/AdVeritasDx\/. Accessed August 10, 2025."},{"issue":"1","key":"i1543-2165-150-5-381-b06","series-title":"Sci Data","first-page":"6","article-title":"The FAIR Guiding Principles for scientific data management and stewardship [erratum in","volume":"6","author":"Wilkinson","year":"2019","unstructured":"Wilkinson MD,\nDumontier M,\nAalbersberg IJ, et al. The FAIR Guiding Principles for scientific data management and stewardship [erratum in Sci Data. 2019;6(1):6. doi:10.1038\/s41597-019-0009-6]. Sci Data. 2016;3:160018. doi:10.1038\/sdata.2016.18"},{"key":"i1543-2165-150-5-381-b07","series-title":"J Am Med Inform Assoc","first-page":"211","article-title":"Structured product labeling improves detection of drug-intolerance issues","volume":"16","author":"Schadow","year":"2009","unstructured":"Schadow G. Structured product labeling improves detection of drug-intolerance issues. J Am Med Inform Assoc. 2009;16:211\u2013219. doi:10.1197\/jamia.M2933"},{"key":"i1543-2165-150-5-381-b08","article-title":"US Food and Drug Administration website","author":"FDA Broad Agency Announcement Day","year":"2022","unstructured":"FDA Broad Agency Announcement Day 2022. US Food and Drug Administration website. December 6, 2022. https:\/\/www.fda.gov\/science-research\/fda-broad-agency-announcement-day-2022-12062022. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b09","article-title":"Diagnostic (LIVD) test code mapping for SARS-CoV-2 tests. Centers for Disease Control and Prevention website","author":"LOINC In Vitro","unstructured":"LOINC In Vitro Diagnostic (LIVD) test code mapping for SARS-CoV-2 tests. Centers for Disease Control and Prevention website. https:\/\/www.cdc.gov\/csels\/dls\/livd-codes.html. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b10","series-title":"Semantic Interoperability for In Vitro Diagnostic Systems","author":"CLSI","year":"2023","unstructured":"CLSI. Semantic Interoperability for In Vitro Diagnostic Systems. 1st ed. CLSI Report AUTO17. Clinical and Laboratory Standards Institute; 2023."},{"key":"i1543-2165-150-5-381-b11","article-title":"Exploring the complexity of COVID-19 diagnostic tests. Center of Complex Interventions website","author":"Wattenberger","unstructured":"Wattenberger A,\nDinakar K,\nSousa J, et al. Exploring the complexity of COVID-19 diagnostic tests. Center of Complex Interventions website. https:\/\/interventions.centerofci.org\/pub\/exploring-covid-test-complexity\/release\/1. Accessed August 10, 2025."},{"key":"i1543-2165-150-5-381-b12","article-title":"COVID-19 RNA testing technology assessment. Center of Complex Interventions website","author":"Farzadfard","unstructured":"Farzadfard F,\nKang L,\nBates S, et al. COVID-19 RNA testing technology assessment. Center of Complex Interventions website. https:\/\/interventions.centerofci.org\/pub\/covid-testing-assessment\/release\/14. Accessed August 10, 2025."},{"key":"i1543-2165-150-5-381-b13","article-title":"Insights from structured SARS-2 diagnostics data. Center of Complex Interventions website","author":"Phillips","unstructured":"Phillips AJ. Insights from structured SARS-2 diagnostics data. Center of Complex Interventions website. https:\/\/interventions.centerofci.org\/pub\/structured-sars-2-diagnostic-data\/release\/1. Accessed August 10, 2025."},{"key":"i1543-2165-150-5-381-b14","article-title":"In vitro diagnostics EUAs\u2014molecular diagnostic tests for SARS-CoV-2","year":"2021","unstructured":"In vitro diagnostics EUAs\u2014molecular diagnostic tests for SARS-CoV-2. US Food and Drug Administration website. 2021. https:\/\/www.fda.gov\/medical-devices\/covid-19-emergency-use-authorizations-medical-devices\/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b15","article-title":"In vitro diagnostics EUAs\u2014antigen diagnostic tests for SARS-CoV-2","year":"2021","unstructured":"In vitro diagnostics EUAs\u2014antigen diagnostic tests for SARS-CoV-2. US Food and Drug Administration website. 2021. https:\/\/www.fda.gov\/medical-devices\/covid-19-emergency-use-authorizations-medical-devices\/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b16","article-title":"In vitro diagnostics Emergency Use Authorizations (EUAs)\u2014serology and other adaptive immune response tests for SARS-CoV-2. 2022. US Food and Drug Administration website","unstructured":"In vitro diagnostics Emergency Use Authorizations (EUAs)\u2014serology and other adaptive immune response tests for SARS-CoV-2. 2022. US Food and Drug Administration website. https:\/\/www.fda.gov\/medical-devices\/covid-19-emergency-use-authorizations-medical-devices\/in-vitro-diagnostics-emergency-use-authorizations-euas-serology-and-other-adaptive-immune-response. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b17","article-title":"Structured SARS-2 diagnostic data. Center of Complex Interventions Archive","author":"Phillips","unstructured":"Phillips AJ,\nBaron V. Structured SARS-2 diagnostic data. Center of Complex Interventions Archive. https:\/\/github.com\/centerofci-archive\/SARS-CoV-2-testing-kit-validation-data\/. Accessed November 26, 2023."},{"key":"i1543-2165-150-5-381-b18","article-title":"Files annotation server","author":"Phillips","unstructured":"Phillips AJ. Files annotation server. Center of Complex Interventions Archive. https:\/\/github.com\/AJamesPhillips\/anot8. Accessed November 26, 2023."},{"key":"i1543-2165-150-5-381-b19","article-title":"Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay","year":"2020","unstructured":"Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay. Wayback Machine website. June 13, 2020. https:\/\/web.archive.org\/web\/20200613101217\/https:\/\/www.fda.gov\/media\/137776\/download. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b20","article-title":"Infinity BiologiX TaqPath SARS-CoV-2","year":"2023","unstructured":"Infinity BiologiX TaqPath SARS-CoV-2. Wayback Machine website. May 11, 2023. https:\/\/web.archive.org\/web\/20230511163511\/https:\/\/www.fda.gov\/media\/137776\/download. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b21","article-title":"Emergency Use Authorization","year":"2021","unstructured":"Emergency Use Authorization. Wayback Machine website. February 28, 2021. https:\/\/web.archive.org\/web\/20210228023054\/https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b22","article-title":"In vitro diagnostics EUAs\u2014molecular diagnostic tests for SARS-CoV-2","year":"2021","unstructured":"In vitro diagnostics EUAs\u2014molecular diagnostic tests for SARS-CoV-2. Wayback Machine website. March 26, 2021. https:\/\/web.archive.org\/web\/20210326223647\/https:\/\/www.fda.gov\/medical-devices\/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b23","article-title":"Abbott RealTime SARS-CoV-2 assay, letter granting EUA amendment(s)","year":"2020","unstructured":"Abbott RealTime SARS-CoV-2 assay, letter granting EUA amendment(s). US Food and Drug Administration website. July 30, 2020. https:\/\/www.fda.gov\/media\/140667\/download?attachment. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b24","article-title":"Abbott RealTime SARS-CoV-2","year":"2020","unstructured":"Abbott RealTime SARS-CoV-2. Wayback Machine website. July 28, 2020. https:\/\/web.archive.org\/web\/20200728165808\/https:\/\/www.fda.gov\/media\/136258\/download. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b25","article-title":"Abbott RealTime SARS-CoV-2","year":"2020","unstructured":"Abbott RealTime SARS-CoV-2. Wayback Machine website. September 5, 2020. https:\/\/web.archive.org\/web\/20200905002031\/https:\/\/www.fda.gov\/media\/136258\/download. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b26","article-title":"Abbott RealTime SARS-CoV-2","year":"2020","unstructured":"Abbott RealTime SARS-CoV-2. Wayback Machine website. September 16, 2020. https:\/\/web.archive.org\/web\/20200916202527\/https:\/\/www.fda.gov\/media\/136258\/download. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b27","series-title":"J Clin Virol","first-page":"105611","article-title":"FDA trial regulation of laboratory developed tests (LDTs): an academic medical center\u2019s experience with Mpox in-house testing","volume":"169","author":"Caldera","year":"2023","unstructured":"Caldera JR,\nGray HK,\nGarner OB,\nYang S. FDA trial regulation of laboratory developed tests (LDTs): an academic medical center\u2019s experience with Mpox in-house testing. J Clin Virol. 2023;169:105611. doi:10.1016\/j.jcv.2023.105611"},{"key":"i1543-2165-150-5-381-b28","article-title":"In Vitro Diagnostic Products for Human Use. 21 CFR Part 809","unstructured":"In Vitro Diagnostic Products for Human Use. 21 CFR Part 809. Electronic Code of Federal Regulations (eCFR). https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-H\/part-809. Accessed January 1, 2025."},{"key":"i1543-2165-150-5-381-b29","series-title":"Am J Clin Pathol","first-page":"730","article-title":"Laboratory-developed tests and in vitro diagnostics: a regulatory overview for anatomic pathology","volume":"163","author":"Genzen","year":"2025","unstructured":"Genzen JR,\nMiller LJ,\nRets AV,\nAffolter KE. Laboratory-developed tests and in vitro diagnostics: a regulatory overview for anatomic pathology. Am J Clin Pathol. 2025;163:730\u2013743."},{"key":"i1543-2165-150-5-381-b30","article-title":"American Clinical Laboratory Association, et al v US Food and Drug Administration, et al (Case No. 4:24-CV-479-SDJ) and Association for Molecular Pathology, et al v US Food and Drug Administration, et al","unstructured":"American Clinical Laboratory Association, et al v US Food and Drug Administration, et al (Case No. 4:24-CV-479-SDJ) and Association for Molecular Pathology, et al v US Food and Drug Administration, et al (Case No. 4:24-CV-824-SDJ) LDT Final Judgment. Association of Molecular Pathology website. https:\/\/www.amp.org\/AMP\/assets\/File\/advocacy\/FDAFinalRule\/LDTFINALJUDGMENT033125.pdf?pass=18. Accessed August 10, 2025."},{"key":"i1543-2165-150-5-381-b31","article-title":"RFC 9110: HTTP semantics. Internet Engineering Task Force website","author":"Fielding","year":"2022","unstructured":"Fielding RT,\nNottingham M,\nReschke J. RFC 9110: HTTP semantics. Internet Engineering Task Force website. 2022. https:\/\/datatracker.ietf.org\/doc\/html\/rfc9110#section-8.8.1. Accessed March 14, 2025."},{"issue":"649","key":"i1543-2165-150-5-381-b32","series-title":"Sci Signal","first-page":"eabe4242","article-title":"COVID-19: all the wrong moves in all the wrong places","volume":"13","author":"Barrett","year":"2020","unstructured":"Barrett CD,\nYaffe MB. COVID-19: all the wrong moves in all the wrong places. Sci Signal. 2020;13(649):eabe4242. doi:10.1126\/scisignal.abe4242"},{"key":"i1543-2165-150-5-381-b33","article-title":"Coronavirus (COVID-19) update: FDA expedites review of diagnostic tests to combat COVID-19. US Food and Drug Administration website","author":"Hahn","year":"2020","unstructured":"Hahn SM. Coronavirus (COVID-19) update: FDA expedites review of diagnostic tests to combat COVID-19. US Food and Drug Administration website. March 30, 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-expedites-review-diagnostic-tests-combat-covid-19. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b34","article-title":"COVID-19 test directory\u2014FIND","author":"FINDDx","unstructured":"FINDDx. COVID-19 test directory\u2014FIND. https:\/\/www.finddx.org\/tools-and-resources\/dxconnect\/test-directories\/covid-19-test-directory\/. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b35","article-title":"Testing Commons. College of Health Solutions website","author":"Aspinall","unstructured":"Aspinall MG,\nWade NL. Testing Commons. College of Health Solutions website. https:\/\/chs.asu.edu\/diagnostics-commons\/testing-commons. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b36","article-title":"COVID-19 Diagnostics Dashboard","unstructured":"COVID-19 Diagnostics Dashboard. PATH website. https:\/\/www.path.org\/programs\/diagnostics\/covid-dashboard-covid-19-diagnostics-dashboard\/. Accessed November 14, 2023."},{"key":"i1543-2165-150-5-381-b37","article-title":"COVID-19 In Vitro Diagnostic Devices and Test Methods Database","year":"2023","unstructured":"COVID-19 In Vitro Diagnostic Devices and Test Methods Database. Joint Research Center website. 2023. https:\/\/covid-19-diagnostics.jrc.ec.europa.eu\/devices. Accessed November 10, 2023."},{"key":"i1543-2165-150-5-381-b38","series-title":"Nat Biotechnol","first-page":"1021","article-title":"The COVID-19 XPRIZE and the need for scalable, fast, and widespread testing","volume":"38","author":"MacKay","year":"2020","unstructured":"MacKay MJ,\nHooker AC,\nAfshinnekoo E, et al. The COVID-19 XPRIZE and the need for scalable, fast, and widespread testing. Nat Biotechnol. 2020;38:1021\u20131024. doi:10.1038\/s41587-020-0655-4"},{"issue":"2","key":"i1543-2165-150-5-381-b39","series-title":"JAMIA Open","first-page":"ooae032","article-title":"Analysis of laboratory data transmission between two healthcare institutions using a widely used point-to-point health information exchange platform: a case report","volume":"7","author":"Luu","year":"2024","unstructured":"Luu HS,\nCampbell WS,\nCholan RA, et al. Analysis of laboratory data transmission between two healthcare institutions using a widely used point-to-point health information exchange platform: a case report. JAMIA Open. 2024;7(2):ooae032. doi:10.1093\/jamiaopen\/ooae032"},{"issue":"1","key":"i1543-2165-150-5-381-b40","series-title":"Ann Lab Med","first-page":"12","article-title":"Laboratory data as a potential source of bias in healthcare artificial intelligence and machine learning models","volume":"45","author":"Luu","year":"2025","unstructured":"Luu HS. Laboratory data as a potential source of bias in healthcare artificial intelligence and machine learning models. Ann Lab Med. 2025;45(1):12\u201321. doi:10.3343\/alm.2024.0323"},{"issue":"8","key":"i1543-2165-150-5-381-b41","series-title":"J Am Med Inform Assoc","first-page":"1372","article-title":"Encoding laboratory testing data: case studies of the national implementation of HHS requirements and related standards in five laboratories","volume":"29","author":"Cholan","year":"2022","unstructured":"Cholan RA,\nPappas G,\nRehwoldt G, et al. Encoding laboratory testing data: case studies of the national implementation of HHS requirements and related standards in five laboratories. J Am Med Inform Assoc. 2022;29(8):1372\u20131380. doi:10.1093\/jamia\/ocac072"},{"issue":"1","key":"i1543-2165-150-5-381-b42","series-title":"Sci Data","first-page":"144","article-title":"The TRUST Principles for digital repositories","volume":"7","author":"Lin","year":"2020","unstructured":"Lin D,\nCrabtree J,\nDillo I, et al. The TRUST Principles for digital repositories. Sci Data. 2020;7(1):144. doi:10.1038\/s41597-020-0486-7"},{"key":"i1543-2165-150-5-381-b43","series-title":"Desirable Characteristics of Data Repositories for Federally Funded Research","author":"The National Science and Technology Council","year":"2022","unstructured":"The National Science and Technology Council. Desirable Characteristics of Data Repositories for Federally Funded Research. NSTC; 2022. doi:10.5479\/10088\/113528"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/150\/5\/article-p381.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/150\/5\/article-p381.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/150\/5\/article-p381.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T02:16:27Z","timestamp":1777256187000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/150\/5\/article-p381.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":86,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.5858\/arpa.2025-0144-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}